You are here

Anthrax Detection Prior to Clinical Presentation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI053977-01
Agency Tracking Number: AI053977
Amount: $152,647.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
7607 EASTMARK DRIVE, SUITE 102
COLLEGE STATION, TX 77840
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SEASON WONG
 (979) 693-0017
 SEASON.WONG@LYNNTECH.COM
Business Contact
 DUNCAN HITCHENS
Phone: (979) 693-0017
Email: DUNCAN.HITCHENS@LYNNTECH.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The technology proposed herein describes an analytical tool for the rapid detection of inhalation anthrax prior to the onset of clinical symptoms. This potentially lethal disease can be fully suppressed in those who are administered antibiotics within 24-48 hours after initial exposure. However, accurate diagnosis can only be achieved using expensive, real-time polymerase chain reaction (PCR) assays (e.g., the LightCycler from Idaho Technology, Inc.) that are not readily available to clinics and hospitals. In the form of an immunochemical Surface Plasmon Resonance (SPR) device and an Amperometric IMmunoSensor (AIMS) electrode assembly, the dual biosensor described in this application will be small enough to incorporate into a handheld device suitable for on-site, clinical use by physicians, nurses, and technicians. The scientific consortium comprised of Lynntech, Inc., the College of Veterinary Medicine and Department of Biochemistry and Biophysics at Texas A&M University (TAMU), and the Department of Microbiology and Molecular Genetics at the University of Texas-Houston Health Science Center Medical School will ensure that all biochemical, medical, and analytical issues of presymptomatic anthrax diagnosis are suitably addressed during the design of this technology.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government